By Stephen Nakrosis


Genentech on Friday said the Food and Drug Administration approved its Tencentriq as an adjuvant treatment for certain lung cancer patients.

The company said Tencentriq, or atezolizumab, was approved as adjuvant treatment following surgery and platinum-based chemotherapy for certain adults with Stage II-IIIA non-small cell lung cancer.

Genentech said Tecentriq is the first and only cancer immunotherapy available for adjuvant treatment of NSCLC.

The company said the approval was based on results from interim analysis of the Phase III IMpower010 study, which showed treatment with Tecentriq improved disease-free survival by over one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with the best supportive care.

Genentech is a member of the Roche Group.


Write to Stephen Nakrosis at


(END) Dow Jones Newswires

October 15, 2021 13:05 ET (17:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Roche (QX) Charts.